# Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

> **NCT05552469** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Myeloid Diseases

## Interventions

- **DRUG:** DFV890

## Key facts

- **NCT ID:** NCT05552469
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2027-01-13
- **Final completion:** 2027-01-13
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552469, "Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05552469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*